Kusumoto T, Maehara Y, Emi Y, Sakaguchi Y, Baba H, Sakaguchi M
Cancer Chemother Pharmacol. 1993; 31(6):455-8.
PMID: 8453684
DOI: 10.1007/BF00685035.
Morgan J, Bleehen N
Br J Cancer. 1981; 44(6):810-8.
PMID: 7326192
PMC: 2010874.
DOI: 10.1038/bjc.1981.279.
Martin W, McNally N, De Ronde J
Br J Cancer. 1981; 43(6):756-66.
PMID: 7248157
PMC: 2010716.
DOI: 10.1038/bjc.1981.113.
Stephens T, COURTENAY V, Mills J, Peacock J, Rose C, Spooner D
Br J Cancer. 1981; 43(4):451-7.
PMID: 7236488
PMC: 2010637.
DOI: 10.1038/bjc.1981.66.
SHELDON P, Batten E, Adams G
Br J Cancer. 1982; 46(4):525-31.
PMID: 7138761
PMC: 2011202.
DOI: 10.1038/bjc.1982.236.
Enhancing effect of pre-treatment of cells with misonidazole in hypoxia on their response to melphalan in air.
Smith E, Stratford I, Adams G
Br J Cancer. 1982; 46(1):117-26.
PMID: 7104191
PMC: 2011057.
DOI: 10.1038/bjc.1982.173.
Effect of clinical levels of misonidazole on the response of tumour and normal tissues in the mouse to alkylating agents.
Brown J, Hirst D
Br J Cancer. 1982; 45(5):700-8.
PMID: 7082556
PMC: 2011020.
DOI: 10.1038/bjc.1982.111.
Growth delay in small EMT6 spheroids induced by cytotoxic drugs and its modification by misonidazole pretreatment under hypoxic conditions.
Twentyman P
Br J Cancer. 1982; 45(4):565-70.
PMID: 7073947
PMC: 2010993.
DOI: 10.1038/bjc.1982.93.
A comparison of adriamycin and mAMSA in vitro: cell lethality and SCE studies.
West C, Stratford I, Barrass N, Smith E
Br J Cancer. 1981; 44(6):798-809.
PMID: 6895696
PMC: 2010861.
DOI: 10.1038/bjc.1981.278.
Enhancement of the DNA cross-linking activity of melphalan by misonidazole in vivo.
Murray D, Meyn R
Br J Cancer. 1983; 47(2):195-203.
PMID: 6824567
PMC: 2011274.
DOI: 10.1038/bjc.1983.27.
An investigation of the possibility of chemosensitization by clinically achievable concentrations of misonidazole.
Twentyman P, Workman P
Br J Cancer. 1983; 47(2):187-94.
PMID: 6824566
PMC: 2011280.
DOI: 10.1038/bjc.1983.26.
In vitro potentiation of BCNU activity in rat brain tumour cells pretreated with misonidazole.
Siemann D, Wolf K, Morrissey S, Wheeler K
Br J Cancer. 1984; 49(6):795-9.
PMID: 6733025
PMC: 1976855.
DOI: 10.1038/bjc.1984.123.
Hypoxic cells and in situ chemopotentiation of the nitrosoureas by misonidazole.
Wheeler K, Wallen C, WOLF K, Siemann D
Br J Cancer. 1984; 49(6):787-93.
PMID: 6733024
PMC: 1976835.
DOI: 10.1038/bjc.1984.122.
Effect of misonidazole pretreatment on nitrogen mustard-induced DNA cross-linking in mouse tissues in vivo.
Murray D, Meyn R
Br J Cancer. 1984; 50(6):801-8.
PMID: 6498077
PMC: 1977012.
DOI: 10.1038/bjc.1984.259.
Chemopotentiation in vivo: no loss of sensitization with fractionation.
Hill S, Siemann D
Br J Cancer. 1984; 50(4):509-17.
PMID: 6487517
PMC: 1976902.
DOI: 10.1038/bjc.1984.208.
Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms.
Horsman M, Evans J, Brown J
Br J Cancer. 1984; 50(3):305-16.
PMID: 6466544
PMC: 1976784.
DOI: 10.1038/bjc.1984.177.
Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721.
Twentyman P
Br J Cancer. 1981; 43(6):745-55.
PMID: 6264941
PMC: 2010713.
DOI: 10.1038/bjc.1981.112.
5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Clinical, pharmacokinetic and in vitro cytotoxicity studies.
Bardakji Z, Jolivet J, Langelier Y, Besner J, Ayoub J
Cancer Chemother Pharmacol. 1986; 18(2):140-4.
PMID: 3791559
DOI: 10.1007/BF00262284.
Bleomycin and misonidazole cytotoxicity.
Korbelik M, Palcic B, SKARSGARD L
Br J Cancer. 1985; 51(4):499-504.
PMID: 2579666
PMC: 1977142.
DOI: 10.1038/bjc.1985.72.
Potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea's toxicity in vitro by two new bioreductive agents.
Papadopoulou M, Mainwaring A, Bloomer W
Jpn J Cancer Res. 1992; 83(8):907-13.
PMID: 1399828
PMC: 5918954.
DOI: 10.1111/j.1349-7006.1992.tb01998.x.